Article

Oligomeric and polymeric aggregates formed by proteins containing expanded polyglutamine

Department of Molecular and Cell Biology, Harvard University, Cambridge, Massachusetts, United States
Proceedings of the National Academy of Sciences (Impact Factor: 9.67). 04/2003; 100(5):2409-14. DOI: 10.1073/pnas.0437660100
Source: PubMed

ABSTRACT

Neurological diseases resulting from proteins containing expanded polyglutamine (polyQ) are characteristically associated with insoluble neuronal inclusions, usually intranuclear, and neuronal death. We describe here oligomeric and polymeric aggregates formed in cells by expanded polyQ. These aggregates are not dissociated by concentrated formic acid, an extremely effective solvent for otherwise insoluble proteins. Perinuclear inclusions formed in cultured cells by expanded polyQ can be completely dissolved in concentrated formic acid, but a soluble protein oligomer containing the expanded polyQ and released by the formic acid is not dissociated to monomer. In Huntington's disease, a formic acid-resistant oligomer is present in cerebral cortex, but not in cerebellum. Cortical nuclei contain a polymeric aggregate of expanded polyQ that is insoluble in formic acid, does not enter polyacrylamide gels, but is retained on filters. This finding shows that the process of polymerization is more advanced in the cerebral cortex than in cultured cells. The resistance of oligomer and polymer to formic acid suggests the participation of covalent bonds in their stabilization.

Download full-text

Full-text

Available from: Guylaine Hoffner
  • Source
    • "Citron et al. 2001; Lai et al. 2007; Monsonego et al. 1997) (Zemaitaitis et al. 2003). To support the role of the transglutaminase activity in the pathogenesis of neurodegenerative diseases, expanded polyglutamine domains, present in HD and other neurodegenerative diseases caused by a CAG expansion in the affected gene, have been reported to be substrates of TG2 in vitro (Gentile et al. 1998; Kahlem et al. 1998; Karpuj et al. 1999; Iuchi et al. 2003). Therefore , aberrant transglutaminase activity could contribute to the pathogenesis of neurodegenerative diseases, including Alzheimer's disease and other neurodegenerative diseases, by different molecular mechanisms, as described in Fig. 4. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Transglutaminases are ubiquitous enzymes, which catalyze post-translational modifications of proteins. Recently, transglutaminases and tranglutaminase-catalyzed post-translational modification of proteins have been shown to be involved in the molecular mechanisms responsible for several human diseases. Transglutaminase activity has been hypothesized to be involved also in the pathogenetic mechanisms responsible for human neurodegenerative diseases. Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, supranuclear palsy, Huntington's disease and other polyglutamine diseases, are characterized in part by aberrant cerebral transglutaminase activity and by increased cross-linked proteins in affected brains. In this review, we focus on the possible molecular mechanisms by which transglutaminase activity could be involved in the pathogenesis of neurodegenerative diseases, and on the possible therapeutic effects of selective transglutaminase inhibitors for the cure of patients with diseases characterized by aberrant transglutaminase activity.
    Full-text · Article · Sep 2011 · Amino Acids
  • Source
    • "Moreover, there is evidence that TGs also contribute to the formation of proteinaceous deposits in Parkinson's disease (PD) [40, 41] and in supranuclear palsy [42, 43]. To support the role of the TG activity in the pathogenesis of neurodegenerative diseases, expanded polyglutamine domains, present in HD and other neurodegenerative diseases caused by a CAG expansion in the affected gene (Table 2) [44], have been reported to be substrates of TG2 in vitro [45–47]. Therefore, aberrant TG activity could contribute to the pathogenesis of neurodegenerative diseases, including Alzheimer's disease and other neurodegenerative diseases, by different molecular mechanisms, as described in Figure 3. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Transglutaminases are ubiquitous enzymes which catalyze posttranslational modifications of proteins. Recently, transglutaminase-catalyzed post-translational modification of proteins has been shown to be involved in the molecular mechanisms responsible for human diseases. Transglutaminase activity has been hypothesized to be involved also in the pathogenetic mechanisms responsible for several human neurodegenerative diseases. Alzheimer's disease and other neurodegenerative diseases, such as Parkinson's disease, supranuclear palsy, Huntington's disease, and other polyglutamine diseases, are characterized in part by aberrant cerebral transglutaminase activity and by increased cross-linked proteins in affected brains. This paper focuses on the possible molecular mechanisms by which transglutaminase activity could be involved in the pathogenesis of Alzheimer's disease and other neurodegenerative diseases, and on the possible therapeutic effects of selective transglutaminase inhibitors for the cure of patients with diseases characterized by aberrant transglutaminase activity.
    Full-text · Article · Feb 2011 · International Journal of Alzheimer's Disease
  • Source
    • "Surprisingly, analysis of the pixel intensities relative to the GAPDH loading controls showed that the average EM48 reactivities for the R6/2 tg/− ;Hsp70 +/+ and R6/2 tg/− ;Hsp70 −/− mice were indistinguishable (Figure 5A and B). Previous studies showed that HD brain homogenates treated with formic acid liberate a SDS-resistant oligomer as analyzed by western immunoblots (Iuchi et al., 2003; Hoffner et al., 2005). Similar to the results observed in HD brain homogenates, we found that treatment of total brain homogenates from R6/2 tg/− ;Hsp70 +/+ mice with formic acid released two bands that reacted with EM48 which migrated at an apparent molecular mass of 70–85 kDa, while concomitantly leading to nearly a complete loss of reactivity in the stacking gel (Figure 5C). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Endogenous protein quality control machinery has long been suspected of influencing the onset and progression of neurodegenerative diseases characterized by accumulation of misfolded proteins. Huntington's disease (HD) is a fatal neurodegenerative disorder caused by an expansion of a polyglutamine (polyQ) tract in the protein huntingtin (htt), which leads to its aggregation and accumulation in inclusion bodies. Here, we demonstrate in a mouse model of HD that deletion of the molecular chaperones Hsp70.1 and Hsp70.3 significantly exacerbated numerous physical, behavioral and neuropathological outcome measures, including survival, body weight, tremor, limb clasping and open field activities. Deletion of Hsp70.1 and Hsp70.3 significantly increased the size of inclusion bodies formed by mutant htt exon 1, but surprisingly did not affect the levels of fibrillar aggregates. Moreover, the lack of Hsp70s significantly decreased levels of the calcium regulated protein c-Fos, a marker for neuronal activity. In contrast, deletion of Hsp70s did not accelerate disease in a mouse model of infectious prion-mediated neurodegeneration, ruling out the possibility that the Hsp70.1/70.3 mice are nonspecifically sensitized to all protein misfolding disorders. Thus, endogenous Hsp70s are a critical component of the cellular defense against the toxic effects of misfolded htt protein in neurons, but buffer toxicity by mechanisms independent of the deposition of fibrillar aggregates.
    Full-text · Article · Aug 2009 · The Journal of Neuroscience : The Official Journal of the Society for Neuroscience
Show more